Latest Posts › Appeals

Share:

2024 Federal Circuit IP Appeals – Amarin Pharma, Inc. v. Hikma Pharm. USA Inc., 104 F.4th 1370 (Fed. Cir. 2024) (Moore, Lourie,...

Amarin sells the drug icosapent ethyl under the brand name Vascepa. Vascepa is approved by the FDA for two indications: (i) to treat severe hypertriglyceridemia, a condition characterized by blood triglyceride levels greater...more

2024 Federal Circuit IP Appeals: Summaries of Key 2024 Decisions

2024 brought exciting developments at the Federal Circuit. The court issued its first en banc decision in a patent case in five years in LKQ, which significantly altered the standard for proving obviousness of a design...more

Federal Circuit IP Appeals: Summaries of Key 2023 Decisions (8th Edition): A Trio of Claim Construction Cases

This year we are covering three claim construction cases from the Federal Circuit—one coming from the Board and the two from district court. Taken together, the cases are a good reminder of the high burden that a party must...more

In Dupree, Supreme Court Unanimously Decides “Purely Legal” Issues Decided at Summary Judgment are Preserved for Appeal

On May 25, 2023, the US Supreme Court issued its opinion in Dupree v. Younger, which resolved a split among the courts of appeals concerning whether “purely legal” issues raised at the summary-judgment stage must be re-raised...more

Federal Circuit Appeals from the PTAB and ITC: Summaries of Key 2021 Decisions

[co-author: Jamie Dohopolski] Last year, the continued global COVID-19 pandemic forced American courts to largely continue the procedures set in place in 2020. The U.S. Court of Appeals for the Federal Circuit was no...more

2/9/2022  /  § 314(d) , 35 U.S.C. §315(e)(1) , Absolute Intervening Rights Doctrine , Abuse of Discretion , Administrative Patent Judges , Administrative Procedure Act , America Invents Act , Appeals , Appointments Clause , Arbitrary and Capricious , Article of Manufacture , Assignor Estoppel , Burden of Proof , Claim Construction , Collateral Estoppel , Commercial Success , Confidential Information , Constitutional Challenges , Demand Letter , Denial of Institution , Design Patent , Director of the USPTO , Dismissals , Doctrine of Prosecution Disclaimer , Due Process , Equitable Estoppel , Estoppel , Evidence , Ex Partes Reexamination , Executive Branch , Executive Powers , Federal Rules of Evidence , Final Written Decisions , Forum Selection , FRCP 52(c) , GATT , Inferior Officers , Intellectual Property Litigation , Intellectual Property Protection , Inter Partes Reexamination , Inter Partes Review (IPR) Proceeding , International Trade Commission (ITC) , Intervening Acts , Inventions , Issue Preclusion , Judicial Review , Lack of Authority , Lack of Jurisdiction , Likelihood of Success , Minerva Surgical Inc. v Hologic Inc. , Motion for Summary Judgment , Motivation to Combine , Nexus , Non-Disclosure Agreement , Nonobvious , Obviousness , Ornamental Design , Parallel Proceedings , Patent Applications , Patent Filings , Patent Infringement , Patent Litigation , Patent Prosecution , Patent Trial and Appeal Board , Patent Validity , Patents , Petition for Writ of Certiorari , Pharmaceutical Patents , Post-Grant Review , Pre-GATT , Preliminary Injunctions , Principle Officers , Printed Publications , Prior Art , Real Party in Interest , Remand , Reversal , Rule 36 , Scope of Review , SCOTUS , Section 325(d) , Sua Sponte , Substantial Evidence , Totality of Evidence , United States v Arthrex Inc , USPTO , Vacated , Writ of Mandamus

PTAB Strategies and Insights - April 2019: The Federal Circuit Clarifies The Notice Requirements Of The Administrative Procedure...

In Nike, Inc. v. Adidas AG, No. 19-1262 (Fed. Cir. Apr. 9, 2020), the Federal Circuit offered important guidance to Patent Trial and Appeal Board (PTAB) litigants regarding how the notice requirements of the Administrative...more

Supreme Court Holds That PTAB Time-Bar Rulings Are Non-Appealable

In Thryv, Inc. v. Click-to-Call Technologies, LP the Supreme Court held, 7-2, that patent owners cannot appeal determinations by the Patent Trial and Appeal Board (PTAB) declining to apply the time-bar of 35 U.S.C. § 315(b)....more

Federal Circuit Appeals From The PTAB: Summaries of Key 2019 Decisions: Regents of the Univ. of Minn. v. LSI Corp., 926 F.3d 1327...

LSI and Ericsson petitioned for inter partes review (IPR) of several patents owned by the University of Minnesota (UMN). UMN moved to dismiss each IPR based on state sovereign immunity. The Patent Trial and Appeal Board...more

Federal Circuit Appeals From The PTAB: Summaries of Key 2019 Decisions

In 2019, the U.S. Court of Appeals for the Federal Circuit docketed just over 650 appeals from the U.S. Patent and Trademark Office (USPTO). That is the highest number since the Court started to hear post-American Invents Act...more

2019 Report: Federal Circuit Appeals from the PTAB - Summaries of Key 2018 Decisions: E.I. Dupont De Nemours & Co. v. Synvina...

DuPont petitioned for inter partes review of Synvina’s patent, which was directed to a method of oxidizing a chemical using a specific temperature range, pressure range, catalyst, and solvent. The prior art disclosed the...more

2019 Report: Federal Circuit Appeals from the PTAB - Summaries of Key 2018 Decisions: Arthrex, Inc. v. Smith & Nephew, Inc., 880...

Smith & Nephew petitioned for inter partes review (IPR) of Arthrex’s patent. After the petition was filed, but before the Board issued an institution decision, Arthrex statutorily disclaimed all the challenged claims under 37...more

18 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide